title: Characterization of pancreastatin receptor and signaling in rat HTC hepatoma cells.
abstract: Pancreastatin, a chromogranin A-derived peptide widely distributed throughout the neuroendocrine system, has a general inhibitory effect on endocrine secretion and a counterregulatory effect on insulin action. We have recently described the cross-talk of pancreastatin with insulin signaling in rat hepatoma cells (HTC), where it inhibits insulin action and signaling through the serine phosphorylation of the insulin receptor, thereby impairing tyrosine kinase activity. Here, we have characterized pancreastatin receptors and signaling in HTC cells. The pancreastatin effector systems were studied by determining phospholipase C activity in HTC membranes and mitogen-activated protein kinase (MAPK) phosphorylation activity in HTC cells. Binding studies with radiolabeled pancreastatin showed a population of high affinity binding sites, with a B(max) of 8 fmol/mg protein and a K(d) of 0.6 nM. Moreover, we assessed the coupling of the receptor with a G protein system by inhibiting the binding with guanine nucleotide and by measuring the GTP binding to HTC membranes. We found that pancreastatin receptor was coupled with a G alpha(q/11) protein which activates phospholipase C-beta(1) and phospholipase C-beta(3), in addition to MAPK via both beta gamma and alpha(q/11).
authors.affiliation: Departamento de Bioquímica Médica y Biología Molecular, Facultad de Medicina, Unidad de Investigación, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Av. Sánchez Pizjuan 4, 41009, Sevilla, Spain. vsanchez@cica.es
authors.forename: V
authors.initials: V
authors.lastname: Sánchez-Margalet
authors.forename: C
authors.initials: C
authors.lastname: González-Yanes
authors.forename: J
authors.initials: J
authors.lastname: Santos-Alvarez
authors.forename: S
authors.initials: S
authors.lastname: Najib
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D002462:Cell Membrane / Q000378:metabolism; D053379:Chromogranin A; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation / Q000187:drug effects; D019204:GTP-Binding Proteins / Q000187:drug effects / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects; D010187:Pancreatic Hormones / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D051381:Rats; D011964:Receptors, Gastrointestinal Hormone / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction; D014407:Tumor Cells, Cultured; D010738:Type C Phospholipases / Q000187:drug effects / Q000378:metabolism
chemical_list: D053379:Chromogranin A; D010187:Pancreatic Hormones; D011964:Receptors, Gastrointestinal Hormone; C029438:receptors, pancreatic polypeptide-specific; C050836:pancreastatin; D010738:Type C Phospholipases; D019204:GTP-Binding Proteins